转移性尿路上皮癌的新兴治疗选择：安维汀（Enfortumab Vedotin）的治疗潜力
Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin.
作者信息
Jain Rohit K, Skelton William Paul, Zhang Jingsong
机构信息
Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
出版信息
Cancer Manag Res. 2020 Sep 11;12:8379-8386. doi: 10.2147/CMAR.S224223. eCollection 2020.
Abstract
Enfortumab vedotin (EV) is an antibody-drug conjugate with humanized anti-Nectin-4 antibody linked with a microtubule-disrupting agent called monomethyl auristatin E. Nectin-4 is a cellular adhesion protein that is overexpressed in urothelial cancer. EV was approved in December 2019 for patients with locally advanced or metastatic urothelial cancer who previously received platinum-based chemotherapy and immune checkpoint inhibitors. Here, we reviewed the clinical efficacy and safety data that led to the accelerated approval of EV for treating patients with metastatic urothelial cancer. Emerging clinical data on EV-based combinational therapeutic trials for metastatic urothelial cancer were also reviewed.
摘要
恩杂鲁胺（EV）是一种抗体药物偶联物，其将人源化抗Nectin-4抗体与一种名为单甲基奥瑞他汀E的微管破坏剂相连。Nectin-4是一种细胞粘附蛋白，在尿路上皮癌中过表达。EV于2019年12月被批准用于先前接受过铂类化疗和免疫检查点抑制剂治疗的局部晚期或转移性尿路上皮癌患者。在此，我们回顾了导致EV加速批准用于治疗转移性尿路上皮癌患者的临床疗效和安全性数据。还回顾了基于EV的转移性尿路上皮癌联合治疗试验的新临床数据。
相似文献
1
Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin.
Cancer Manag Res. 2020 Sep 11;12:8379-8386. doi: 10.2147/CMAR.S224223. eCollection 2020.
2
Enfortumab Vedotin in urothelial cancer.
Ther Adv Urol. 2020 Dec 27;12:1756287220980192. doi: 10.1177/1756287220980192. eCollection 2020 Jan-Dec.
3
Enfortumab vedotin to treat urothelial carcinoma.
Drugs Today (Barc). 2020 May;56(5):329-335. doi: 10.1358/dot.2020.56.5.3127027.
4
Enfortumab vedotin in the treatment of urothelial cancers and beyond.
Future Oncol. 2022 Sep;18(27):3067-3084. doi: 10.2217/fon-2022-0328. Epub 2022 Aug 25.
5
The biology and rationale of targeting nectin-4 in urothelial carcinoma.
Nat Rev Urol. 2021 Feb;18(2):93-103. doi: 10.1038/s41585-020-00394-5. Epub 2020 Nov 25.
6
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Invest New Drugs. 2020 Aug;38(4):1056-1066. doi: 10.1007/s10637-019-00844-x. Epub 2019 Aug 14.
7
Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
Cancer Manag Res. 2023 Jul 18;15:699-706. doi: 10.2147/CMAR.S418009. eCollection 2023.
8
Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context.
Onco Targets Ther. 2022 Dec 15;15:1519-1529. doi: 10.2147/OTT.S370900. eCollection 2022.
9
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Expert Rev Anticancer Ther. 2022 May;22(5):449-455. doi: 10.1080/14737140.2022.2069563. Epub 2022 Apr 26.
10
Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
Curr Urol. 2023 Dec;17(4):271-279. doi: 10.1097/CU9.0000000000000204. Epub 2023 May 5.
引用本文的文献
1
Anti-Cancer Drug-Induced Lyell's Syndrome: A Series of Two Patients.
Curr Oncol. 2024 Nov 4;31(11):6891-6897. doi: 10.3390/curroncol31110509.
2
Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer.
Biomedicines. 2023 Jun 1;11(6):1610. doi: 10.3390/biomedicines11061610.
3
Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
Pharmaceutics. 2022 Feb 11;14(2):396. doi: 10.3390/pharmaceutics14020396.
4
Cutaneous reactions with enfortumab vedotin: A case series and review of the literature.
JAAD Case Rep. 2021 Jun 4;14:7-9. doi: 10.1016/j.jdcr.2021.05.020. eCollection 2021 Aug.
5
Nectin-4 and p95-ErbB2 cooperatively regulate Hippo signaling-dependent SOX2 gene expression, enhancing anchorage-independent T47D cell proliferation.
Sci Rep. 2021 Apr 1;11(1):7344. doi: 10.1038/s41598-021-86437-2.
6
Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
Drug Des Devel Ther. 2021 Feb 11;15:453-462. doi: 10.2147/DDDT.S240854. eCollection 2021.
本文引用的文献
1
Epidemiology of Bladder Cancer.
Med Sci (Basel). 2020 Mar 13;8(1):15. doi: 10.3390/medsci8010015.
2
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
J Clin Oncol. 2020 Apr 1;38(10):1041-1049. doi: 10.1200/JCO.19.02044. Epub 2020 Feb 7.
3
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
4
Erdafitinib for the treatment of metastatic bladder cancer.
Expert Rev Clin Pharmacol. 2020 Jan;13(1):1-6. doi: 10.1080/17512433.2020.1702025. Epub 2019 Dec 22.
5
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Invest New Drugs. 2020 Aug;38(4):1056-1066. doi: 10.1007/s10637-019-00844-x. Epub 2019 Aug 14.
6
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
J Clin Oncol. 2019 Oct 10;37(29):2592-2600. doi: 10.1200/JCO.19.01140. Epub 2019 Jul 29.
7
Immunotherapy Advances in Urothelial Carcinoma.
Curr Treat Options Oncol. 2018 Dec 15;19(12):79. doi: 10.1007/s11864-018-0598-x.
8
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.
9
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Cancer Res. 2016 May 15;76(10):3003-13. doi: 10.1158/0008-5472.CAN-15-1313. Epub 2016 Mar 24.
10
The immunoglobulin-like cell adhesion molecule nectin and its associated protein afadin.
Annu Rev Cell Dev Biol. 2008;24:309-42. doi: 10.1146/annurev.cellbio.24.110707.175339.
Zotero 插件